(Q38040708)

English

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

scientific article published on 04 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

0 references

1 reference

based on heuristic

inferred from title

Martin Bornhäuser

5

object named as

Martin Bornhäuser

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

11

object named as

Bob Löwenberg

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

2

object named as

Alois Gratwohl

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Dietger Niederwieser

13

object named as

Dietger Niederwieser

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

author name string

Jan J Cornelissen

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Richard F Schlenk

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Jorge Sierra

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Gunnar Juliusson

6

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Zdenek Råcil

7

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Jacob M Rowe

8

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Nigel Russell

9

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Mohamad Mohty

10

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Gerard Socié

12

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Gert J Ossenkoppele

14

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

language of work or name

0 references

publication date

4 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Nature Reviews Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

579-590

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Independent prognostic variables in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Treatment of acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Molecular signatures in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

DNMT3A Mutations in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Monitoring of minimal residual disease in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

The EBMT risk score

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Twenty-five years of peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantat

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients underg

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Reduced mortality after allogeneic hematopoietic-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

HLA matching in allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Risk assessment in haematopoietic stem cell transplantation: conditioning

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Busulfan in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Reduced-intensity conditioning transplantation in myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the F

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Umbilical cord blood transplantation for myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Long-term survival and late deaths after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Risk Factors for Late Infections after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Related Donor

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Nonmalignant late effects after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Solid cancers after bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transpla

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Treatment of chronic graft-versus-host disease in 2011

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Developments in T-cell depletion of allogeneic stem cell grafts

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Long-term follow-up of T-cell depletion for bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.150

31 March 2020

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22949046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22949046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRCLINONC.2012.150

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38040708&oldid=2171604509"